Search

Your search keyword '"Adank, M.A."' showing total 96 results

Search Constraints

Start Over You searched for: Author "Adank, M.A." Remove constraint Author: "Adank, M.A."
96 results on '"Adank, M.A."'

Search Results

1. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families

2. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases

3. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

5. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

6. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

7. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

8. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

9. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

10. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

11. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

12. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

13. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

14. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.

15. Cancer risks for other sites in addition to breast in CHEK2c.1100delC families

16. Design and overview of the Origins of Alzheimer’s Disease Across the Life course (ORACLE) study

17. Gestational lipid profile as an early marker of metabolic syndrome in later life: a population-based prospective cohort study

18. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.

19. Prediction and clinical utility of a contralateral breast cancer risk model.

20. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

21. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts

22. Maternal cardiovascular adaptation to twin pregnancy: A population-based prospective cohort study

23. Fetal sex and maternal pregnancy outcomes: a systematic review and meta-analysis

24. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity

25. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

26. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

27. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

28. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.

29. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers

30. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

31. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

32. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

34. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

36. Performance of BRCA1/2 mutation prediction models in male breast cancer patients

37. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk

38. Performance of BRCA1/ 2 mutation prediction models in male breast cancer patients

40. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

41. Age-And tumor subtype-specific breast cancer risk estimates for CHEK2∗1100delC Carriers

42. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

43. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?

44. MicroRNA related polymorphisms and breast cancer risk

45. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer]

46. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

47. Clinical impact of breast cancer genes

48. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

49. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study.

50. MicroRNA related polymorphisms and breast cancer risk

Catalog

Books, media, physical & digital resources